Chugai Pharmaceutical Co Ltd ADR (CHGCY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Chugai Pharmaceutical Co Ltd ADR (CHGCY) is down 9.4% since the beginning of the year. At $24 per share, CHGCY is trading 31.7% below its 52-week high of $35. Investors who bought $1,000 worth of CHGCY shares 5 years ago would now be looking at an investment worth $1,303.

Chugai Pharmaceutical Co Ltd ADR (CHGCY) has returned -9.40% so far this year and -10.93% over the past 12 months. Looking at the last ten years, CHGCY has achieved an annualized return of 15.87%, outperforming the S&P 500 Index benchmark, which averaged 13.75% per year.

Based on dividend-adjusted daily data since Nov 23, 2010, CHGCY's average daily return is +0.07%, while the average monthly return is +1.50%. At this rate, an investment would double in approximately 3.9 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jul 2014 with a return of +28.1%, while the worst month was Dec 2014 at -20.5%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 4 months.

On a daily basis, CHGCY closed higher 28% of trading days. The best single day was Oct 2, 2018 with a return of +25.9%, while the worst single day was Aug 7, 2025 at -20.0%.

Chugai Pharmaceutical Co Ltd ADR has an annualized alpha of 15.55%, beta of 0.29, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since November 24, 2010.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (55.47%) than losses (12.46%) - typical of diversified or defensive assets.
• Beta of 0.29 may look defensive, but with R2 of 0.03 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CHGCY ranks 28 for risk / return — below 28% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Chugai Pharmaceutical Co Ltd ADR (CHGCY) and compare them to S&P 500 Index.

Chugai Pharmaceutical Co Ltd ADR provided a 1.79% dividend yield over the last twelve months, with an annual payout of $0.43 per share.

The table displays the monthly dividend distributions for Chugai Pharmaceutical Co Ltd ADR. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Chugai Pharmaceutical Co Ltd ADR. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Chugai Pharmaceutical Co Ltd ADR was 59.68%, occurring on Nov 9, 2022. Recovery took 610 trading sessions.

The current Chugai Pharmaceutical Co Ltd ADR drawdown is 29.19%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Chugai Pharmaceutical Co Ltd ADR over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Chugai Pharmaceutical Co Ltd ADR is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.